Metastatic Hormone-Sensitive Prostate Cancer
Pipeline by Development Stage
Drug Modality Breakdown
Metastatic Hormone-Sensitive Prostate Cancer is a $4.2B market at peak maturity, dominated by four androgen-targeting therapies with limited near-term disruption.
Key Trends
- Androgen Receptor (AR) antagonists represent 100% of the market; class dominance is absolute
- Three products (XTANDI, ERLEADA, NUBEQA) in peak lifecycle with patents extending to 2037–2042
- Clinical pipeline shows 29 trials but limited primary indication focus; most activity is in combination or resistance settings
Career Verdict
Solid but consolidating opportunity—strong for commercial and medical affairs roles at J&J and Bayer, but limited upside growth and pipeline depth suggest this is a mature specialty area.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | XTANDI (ENZALUTAMIDE) | Astellas | $2.6B | 62% | PEAK | Stable | 10.7yr |
| 2 | ERLEADA (APALUTAMIDE) | Johnson & Johnson | $1.1B | 26% | PEAK | Stable | 13.7yr |
| 3 | NUBEQA (DAROLUTAMIDE) | Bayer | $576M | 14% | PEAK | Stable | 16.1yr |
| 4 | YONSA (ABIRATERONE ACETATE) | Fosun Pharma | $14M | 0% | PEAK | Declining | 8.0yr |
Drug Class Breakdown
market leader; stable
strong competitor; stable
emerging third option; stable
niche/declining
Career Outlook
StablemHSPC is a mature, consolidated market with entrenched players and limited pipeline innovation; career growth is tied to defending market share, optimizing commercial execution, and managing patent cliff transitions rather than building new franchises. J&J's dominance (99.8% of jobs) creates concentration risk for specialists—moves between companies are difficult. The absence of emerging mechanisms (ADCs, bispecifics, immunotherapy combinations) signals that this disease area will not attract significant capital or talent reallocation in the next 5 years.
Breaking In
Target entry-level Commercial or Clinical Operations roles at J&J if you seek stable employment in oncology; expect 5–7 year tenure before seeking growth in higher-risk, earlier-stage disease areas or therapeutic classes.
For Experienced Professionals
Specialists with 8+ years in mHSPC should prioritize skill diversification (e.g., health economics, digital health, real-world evidence) or pivot to earlier-stage prostate cancer indications (castration-resistant) or unrelated high-growth oncology areas to future-proof career trajectory.
In-Demand Skills
Best For
Hiring Landscape
1,802 jobs identified across four companies, with 99.8% concentrated at Johnson & Johnson (1,798 jobs) and Bayer (4 jobs), reflecting J&J's dominance via ERLEADA and broader oncology infrastructure. Commercial and Clinical Operations roles comprise 526 jobs (29%), while R&D and Medical Affairs (136 jobs, 7.5%) reflect mature-stage optimization rather than discovery-stage expansion. Salaries range from $133K (Manufacturing) to $212K (Medical Affairs), with Commercial roles averaging $170K.
By Department
Strong hiring volume at J&J provides job security and career pathways in commercial and clinical operations, but limited openings at competitors and heavy engineering/non-pharma skew suggest this is not a growth-stage hiring environment.
Competitive Landscape
8 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (5)
Total enrollment: 3,213 patients across 5 trials
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Related Jobs in Oncology
Senior Virology Care Specialist
Sr. Biosample Manager
Oncology Account Manager, North Central
(Assoc.) Director, Clinical Development Scientist-Urologic Oncology
(Sr.) Medical Director, Oncology
Oncology Home Infusion Nurse (RN)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.